122375-70-6

Usage

Uses

Used in Organic Synthesis:
3-AMINO-5-PHENYLTHIOPHENE-2-CARBOXAMIDE is used as a key intermediate in organic synthesis for the production of various pharmaceuticals and agrochemicals. Its unique structure allows for the formation of diverse chemical entities with potential therapeutic and pesticidal properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-AMINO-5-PHENYLTHIOPHENE-2-CARBOXAMIDE serves as a building block for the design and synthesis of novel drug candidates. Its presence in the molecular structure can influence the pharmacokinetic and pharmacodynamic properties of the resulting compounds, contributing to their efficacy and safety profiles.
Used in Material Science:
3-AMINO-5-PHENYLTHIOPHENE-2-CARBOXAMIDE is utilized in the development of new materials with electronic and optoelectronic properties. Its incorporation into these materials can enhance their performance in various applications, such as sensors, solar cells, and light-emitting diodes.
Used in Organic Electronics:
In the realm of organic electronics, 3-AMINO-5-PHENYLTHIOPHENE-2-CARBOXAMIDE is employed as a component of organic semiconductors. Its electronic properties make it a valuable contributor to the performance of organic field-effect transistors, organic photovoltaics, and other electronic devices.
Used in Research and Development:
3-AMINO-5-PHENYLTHIOPHENE-2-CARBOXAMIDE is also used in research and development settings to explore its potential applications and properties further. Scientists and chemists investigate its reactivity, stability, and interactions with other molecules to uncover new uses and improve existing ones across various industries.

InChI:InChI=1/C11H10N2OS/c12-8-6-9(15-10(8)11(13)14)7-4-2-1-3-5-7/h1-6H,12H2,(H2,13,14)

Upstream product

• 83060-72-4 3-amino-5-phenylthiophene-2-carbonitrile 
• 99972-47-1 3-amino-5-phenyl-2-thiophenecarboxylic acid 
• 100063-22-7 methyl 3-amino-5-phenylthiophene-2-carboxylate 

Downstream Products

• 1215310-66-9 6-phenyl-3H-thieno[3,2-d][1,2,3]-triazin-4-one 

Relevant academic research and scientific papers

ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS

The present invention discloses triazene analogs of the general formula (I) and formula (II), their tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts thereof for the metastatic malignant melanoma and other cancers including but not limited to lymphomas, sarcomas, carcinomas, and gliomas. The invention further discloses a process for the preparation of the above said triazene analogs of formula (I) and formula (II), and their pharmaceutically acceptable compositions.

ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS

The present invention discloses triazene analogs of the general formula (I) and formula (II), their tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts thereof for the metastatic malignant melanoma and other cancers including but not limited to lymphomas, sarcomas, carcinomas, and gliomas. The invention further discloses a process for the preparation of the above said triazene analogs of formula (I) and formula (II), and their pharmaceutically acceptable compositions.

Evolution of the thienopyridine class of inhibitors of IκB kinase-β: Part I: Hit-to-lead strategies

High-throughput screening is routinely employed as a method for the identification of novel hit structures. Large numbers of active compounds are typically procured in this way and must undergo a rigorous validation process. This process is described in detail for a collection of screening hits identified as inhibitors of IκB kinase-β (IKKβ), a key regulatory enzyme in the nuclear factor-κB (NF-κB) pathway. From these studies, a promising hit series was selected. Subsequent lead generation activities included the development of a pharmacophore hypothesis and structure-activity relationship (SAR) for the hit series. This led to the exploration of related scaffolds offering additional opportunities, and the various structural classes were comparatively evaluated for enzyme inhibition, selectivity, and drug-like properties. A novel lead series of thienopyridines was thereby established, and this series advanced into lead optimization for further development.

Hit-to-lead studies: The discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors

A hit-to-lead optimisation programme was carried out on the thiophenecarboxamide high throughput screening hits 1 and 2 resulting in the discovery of the potent and orally bioavailable IKK-2 inhibitor 22.